Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis.

Okuno, Taishi; Tomii, Daijiro; Buffle, Eric; Lanz, Jonas; Ryffel, Christoph; Demirel, Caglayan; Hashemi, Suliman; Hagemeyer, Daniel; Papadis, Athanasios; Heg, Dik; Praz, Fabien; Stortecky, Stefan; Windecker, Stephan; Pilgrim, Thomas (2022). Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis. Heart, 108(15), pp. 1225-1233. BMJ Publishing Group 10.1136/heartjnl-2021-320531

Preview	Text Okuno_Heart_2022_AAM.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (452kB) | Preview
	Text Okuno_Heart_2022.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)
	Text Okuno_Heart_2022_supplmat.pdf - Supplemental Material Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB)
	Video Okuno_Heart_2022_supplmat_video.mp4 - Supplemental Material Restricted to registered users only Available under License Publisher holds Copyright. Download (17MB)

BACKGROUND

Rheumatic heart disease (RHD) accounts for the highest number of deaths from valvular heart disease globally. Yet, rheumatic aortic stenosis (AS) was excluded from landmark studies investigating the safety and efficacy of transcatheter aortic valve implantation (TAVI). We aimed to describe the clinical and anatomical characteristics of patients with rheumatic AS undergoing TAVI, and to compare procedural and clinical outcomes with patients undergoing TAVI for degenerative AS.

METHODS

In a prospective TAVI registry, patients with rheumatic AS were identified based on International Classification of Diseases version 10 codes and/or a documented history of acute rheumatic fever and/or the World Heart Federation criteria for echocardiographic diagnosis of RHD, and were propensity score-matched in a 1:4 ratio to patients with degenerative AS.

RESULTS

Among 2329 patients undergoing TAVI, 105 (4.5%) had rheumatic AS. Compared with patients with degenerative AS, patients with rheumatic AS were more commonly female, older, had higher surgical risk and more commonly suffered from multivalvular heart disease. In the unmatched cohort, both technical success (85.7% vs 85.9%, p=0.887) and 1-year cardiovascular mortality (10.0% vs 8.6%; HR 1.16, 95% CI 0.61 to 2.18, p=0.656) were comparable between patients with rheumatic and degenerative AS. In contrast, patients with rheumatic AS had lower rates of 30-day and 1-year cardiovascular mortality compared with matched patients with degenerative AS (1.9% vs 8.9%, adjusted HR (HRadj) 0.18, 95% CI 0.04 to 0.80, p=0.024; and 10.0% vs 20.3%, HRadj 0.44, 95% CI 0.24 to 0.84, p=0.012, respectively).

CONCLUSION

TAVI may be a safe and effective treatment strategy for selected elderly patients with rheumatic AS.

TRIAL REGISTRATION NUMBER

NCT01368250.

Interest & Impact

Downloads

234 since deposited on 31 Mar 2022
106 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item